ArticleFrontiers in psychiatry2023
Effect of esketamine on postoperative depressive symptoms in patients undergoing thoracoscopic lung cancer surgery: A randomized controlled trial.
Article in Frontiers in psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06718231 (Transcutaneous Electrical Acupoint Stimulation Alleviate Postoperative Depression in Video-assisted Thoracoscopic Surgery), which is not on this map. Cited by 18 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Transcutaneous Electrical Acupoint Stimulation Alleviate Postoperative Depression in Video-assisted Thoracoscopic Surgery: a Randomized Controlled Trial
Who cites it
18 citing papers in PubMed, 6 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- The effectiveness of exercise interventions on psychological distress in patients with lung cancer: a systematic review and meta-analysis.Journal of cancer survivorship : research and practice · 2026Pooled it
- Efficacy and safety of esketamine on major depression, postpartum depression and perioperative depression: a systematic review and meta-analysis.Molecular psychiatry · 2026Pooled it
- The application of esketamine in cancer-related depressive states: attention from mechanisms to clinical translation.Frontiers in psychiatry · 2026Pooled it
- Effects of esketamine on postoperative delirium in adult patients: a systematic review and meta-analysis of randomized controlled trials.Frontiers in neurology · 2026Pooled it
- Efficacy of esketamine on perioperative anxiety in patients receiving anesthesia: a systematic review and meta-analysis of RCTs.Frontiers in psychiatry · 2026Pooled it
- Efficacy of perioperative esketamine on postoperative depression: a systematic review and meta-analysis.Frontiers in psychiatry · 2025Pooled it
- Esketamine vs. sufentanil for quality of recovery after outpatient gynecological surgery: a randomized clinical trial.Annals of medicine · 2026Trial
- Esketamine-sufentanil PCA reduces postoperative depression state in elderly colorectal cancer patients: a randomized controlled trial.Scientific reports · 2026Trial
- Effect of subanesthetic dose esketamine on anxiety and depression in patients with breast cancer after surgery: a randomized controlled, double-blind study.BMC psychiatry · 2026Trial
- Esketamine for Postoperative Anxiety After Major Abdominal Tumor Surgery: A Randomized Clinical Trial.Drug design, development and therapy · 2026Trial
- Subanesthetic Dose of Esketamine Improves the Sedative and Analgesic Effects of Dexmedetomidine and Remifentanil in Liposuction Anesthesia: A Prospective, Double-Blinded, Randomized Controlled Trial.Drug design, development and therapy · 2024Trial
- Effects of Intravenous Esketamine or Magnesium Sulfate on Early Postoperative Negative Emotions and Pain in Patients Undergoing Endoscopic Sinus Surgery: A Randomized Controlled Trial.Therapeutics and clinical risk management · 2026Article
- Effect of low-dose esketamine on postoperative quality of recovery in total laparoscopic hysterectomy: a randomized controlled trial.Perioperative medicine (London, England) · 2025Article
- Effects of the subanesthetic dose of esketamine on postoperative sleep quality in patients undergoing modified radical mastectomy: a randomized, double-blind controlled trial.Frontiers in medicine · 2025Article
- Esketamine for postoperative sleep disturbance: clinical evidence, mechanisms, and future directions.Frontiers in psychiatry · 2025Review
- Herbal Cannabis and Depression: A Review of Findings Published over the Last Three Years.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Effects of ketamine on the severity of depression and anxiety following postoperative mechanical ventilation: a single-blind randomized clinical trial in Iran.Acute and critical care · 2024Article
- An Intraoperative Sub-Anesthetic Dose of Esketamine on Postoperative Depressive Symptoms in Perimenopausal Women with Breast Cancer Undergoing Modified Radical Mastectomy: Protocol for a Randomized, Triple-Blinded, Controlled Trial.International journal of general medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Depressive symptoms are common among patients with lung cancer. We aimed to assess the effects of esketamine on postoperative depressive symptoms after thoracoscopic lung cancer surgery. Methods: In this randomized, double-blind, placebo-controlled trial, 156 patients undergoing thoracoscopic lung cancer surgery were randomly allocated in a 1:1 ratio to receive intravenous esketamine (intraoperatively and in patient-controlled analgesia until 48 h postoperatively) or normal saline placebo. The primary outcome was the proportion of patients with depressive symptoms at 1 month postoperatively, assessed using the Beck Depression Inventory-II (BDI-II). Secondary outcomes included depressive symptoms at 48 h postoperatively, hospital discharge and 3 months postoperatively, BDI-II scores, anxious symptoms, Beck Anxiety Inventory scores, Quality of Recovery-15 (QoR-15) scores, and 1- and 3-month mortality. Main results: A total of 151 patients (75 in the esketamine group and 76 in the normal saline group) completed the 1-month follow-up. The esketamine group had a significantly lower incidence of depressive symptoms at 1 month compared to the normal saline group (1.3% vs. 11.8%; risk difference = -10.5, 95%CI = -19.6% to -0.49%; Conclusion: Perioperative administration of esketamine reduced the incidence of depressive symptoms at 1 month after thoracoscopic lung cancer surgery. History of hypertension and preoperative anxious symptoms were independent risk factors for depressive symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.